Products
Hepatitis B Vaccine Hansenula Polymorpha
AIM Honesty Biopharmaceutical Co., Ltd. is a professional manufacturer and independently developed RECVAX® Hepatitis B Vaccine Hansenula Polymorpha. Due to the adoption of the first domestic and internationally leading recombinant Hansenula Polymorpha expression technology platform and patented adjuvant technology, it has achieved excellent immune effects, even surpassing the same dose of imported products, and even the domestic multiple-dose products.
Hepatitis B Vaccine Hansenula Polymorpha is a product developed and manufactured by AIM Honesty Biopharmaceutical Co., Ltd., a professional vaccine manufacturer from China.
This vaccine is suitable for individuals susceptible to hepatitis B, especially the following groups:
1. Newborns, particularly those whose mothers are HBsAg and HBeAg positive.
2. Healthcare workers and laboratory personnel who work in medical settings and are exposed to blood.
Product Specification
Compared to other technical routes, RECVAX® were produced with a more rigorous pharmacopeia standard, which improve the quality and safety of the product.
| Pharmacopoeia Item | Endotoxin content | Free formaldehyde | Thiocyanate | Residual amount of antibiotics | Residual amount of bovine serum albumin |
| Hansenula polymorpha | Less than 5 EU/ml | Less than 15 µg/ml | Not applicable | Not applicable | Not applicable |
| Saccharomyces cerevisiae | Less than 5 EU/ml | Less than 20 µg/ml | Should be less than 1 µg/ml | Not applicable | Not applicable |
| CHO cells | Less than 10 EU/ml | Less than 50 µg/ml | Not applicable | No more than 50 ng/dose | No more than 50 ng/dose |
| Process | Hansenula Yeast | Saccharomyces Yeast | CHO Cell |
| Process Description | Most advanced process | First generation yeast expression system | Most dated process |
| Tumorigenic Risk? | No | No | Yes |
| Antibiotic Added? | No | No | Yes |
| Bovine Serum Albumin Added? | No | No | Yes |
| Animal Pathogen Risk? | No | No | Yes |
| Thiocyanate Added? | No | Yes | No |
| Immunogenicity | High | Higher | Not much (general double dose vs. yeast shows poor response) |
| Vaccine Purity | Highest | Higher | More additives, lower purity |
| Potential Benefit | Strongest cellular immunity induction | Second strongest cellular immunity induction | Weakest cellular immunity induction |
| Representative Product Statement | 10 µg applicable to all populations | 10 µg applicable only to children | 10 µg immunogenicity poor, almost discontinued |
Product Feature And Application
RECVAX® patented adjuvant technology, through in situ adsorption technology, creates an "antigen bank" in the body after the product enters, steadily releasing antigens, extending the duration of antigen action, playing a role in enhancing the stimulation of the immune response, and improving immunogenicity.
The RECVAX® series Hepatitis B Vaccine Hansenula Polymorpha has been on the market for 20 years, covering 31 provinces, cities, and autonomous regions in the country, with a total market usage of nearly 500 million doses, providing immunization plans for nearly 80% of the country's newborns.
A study led by Academician Li Lanjuan evaluated booster immunization in 5- to 15-year-old children with four different hepatitis B vaccines. After a 0-1-6-month booster series with 10 μg RECVAX® (Hansenula-yeast) vaccine, the anti-HBs seropositive rates at 1, 5, and 8 years post-booster reached 83.4 %—the highest among all four vaccines evaluated.
Production Details
Professional and modern production workshops are the cornerstone of high-quality products!
Hot Tags: Hepatitis B Vaccine Hansenula Polymorpha, China, Manufacturer, Supplier, Factory
Send Inquiry
Contact Info
-
Address
● 26F, T6, Dazu Square, NO.2 Ronghua South Road, ETDZ, Beijing, China
● 10F, Port Building, 1 Fenghe Road, Pudong, Shanghai, China -
Tel
-
E-mail
For inquiries about human rabies vaccine, hepatitis B vaccine, hepatitis A vaccine or price list, please leave your email to us and we will be in touch within 24 hours.
